

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**ATTY. DOCKET NO.
1662/53606SERIAL NO.
10/758,026APPLICANT
Jean HILDESHEIM et al.FILING DATE
January 16, 2004GROUP
Not Yet Assigned**U. S. PATENT DOCUMENTS**

| EXAMINER INITIAL | PATENT NUMBER | PATENT DATE | NAME | CLASS | SUB- CLASS | FILING DATE* |
|---------------------|------------------|-------------------|------------------|-------|---------------|-----------------|
| | 4,503,067 | March 5, 1985 | Wiedemann et al. | | | |
| | *5,071,868 | December 10, 1991 | Herbert Leinert | | | |

*Copy of reference enclosed.

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|---------------------|--------------------|------------------|---------|-------|----------|---------------------|----|
| | | | | | | YES | NO |
| | 0 127 099 B1 | May 20, 1987 | Europe | | | | X |
| | 0 918 055 | May 26, 1999 | Europe | | | English Document | |
| | WO 99/05105 | Feb. 4, 1999 | PCT | | | English Document | |
| | *EP 0 127 099 A | December 5, 1984 | Europe | | | Abstract | |

*Copy of reference enclosed.

OTHER DOCUMENTS

| EXAMINER INITIAL | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC. |
|---------------------|--|
| | G.M. Wall, "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No. 2, pages 33-42, February 1986. |
| | J.K. Haleblan and W. McCrone, "Pharmaceutical Applications of Polymorphism", Journal of Pharmaceutical Sciences, Vol. 58, No. 8, pages 911-929, July 1969. |
| | J.K. Haleblan, "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications", Journal of Pharmaceutical Sciences, Vol. 64, No. 8, pages 1269-1288, July 1975. |
| | Pharmacopeial Forum, Vol. 24, No. 1, pages 5438-5441, January - February 1998. |
| | SENDEROFF et al., "Synthesis of the Enantiomers and Three Racemic Metabolites of Carvedilol Labeled to High Specific Activity With Tritium", Journal of Labeled Compounds and Radiopharmaceuticals, December 1993, Vol. 33, No. 12, pages 1091-1105. |
| | *Chen, Wei-Min et al. "Synthesis and Crystal Structure of Carvedilol" JIEGOU HUAXUE, Vol. 17, No. 5, Sept. 1998, pages 325-328 (abstract included). |
| | *Carey, Francis A. et al. "Advanced Organic Chemistry" Third Edition, Part A: Structure and Mechanisms; Plenum Press, pp. 232-239. |

*Copy of reference enclosed.

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

| | | | |
|---|---------------------------------|--|------------------------------|
| INFORMATION DISCLOSURE STATEMENT | | Docket Number: 1662/53606 | |
| Application Number 10/758,026 | Filing Date January 16, 2004 | Examiner Not Yet Assigned | Art Unit Not Yet Assigned |
| Title CARVEDILOL | | Applicant(s) Jean HILDESHEIM et al. | |

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Date: 29 April 2004 Reg. No. 38,413

Signature: _____

Joseph A. Coppola
Joseph A. Coppola

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies are enclosed of each patent, publication or other information listed on the modified PTO Form 1449 marked with an asterisk. Otherwise, copies of each patent, publication or other information listed on the modified PTO Form 1449 are not enclosed since they were previously cited by or submitted to the Patent Office in a prior application, Serial No. 09/894,798, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.

Dated: APRIL 29, 2004

By: _____

Joseph A. Coppola
Joseph A. Coppola (Reg. No. 38,413)

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646